Table 3 Results of multivariate analysis restricted for IDH2+ patients in different genetic subgroups of NK-AML patients.

From: IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen

End point and variables

 

P value

Total NK-AML (n = 50)

CR rate after 1st induction

OR (95% CI)

 

Age (continuous)

0.97 (0.92–1.033)

0.38*

CEBPA double mut

1.06 (0.33–3.4)

0.92*

NPM1 mut

1.9 (0.4–9.09)

0.4*

FLT3-ITD

1.77 (0.12–26.18)

0.66*

DAC versus DA

2.04 (0.49–8.41)

0.3*

4-year OS

HR (95% CI)

 

Age (continuous)

1.04 (0.99–1.09)

0.12**

CEBPA double mut

1.8 (0.2–15.3)

0.57**

NPM1 mut

0.25 (0.067–0.92)

0.038**

FLT3-ITD

3.2 (0.578–17.54)

0.18**

DAC versus DA

0.39 (0.14–1.1)

0.076**

4-year OS censored at allograft

HR (95% CI)

 

Age (continuous)

1.03 (0.97–1.1)

0.3**

CEBPA double mut

1.6 (0.18–13.7)

0.66**

NPM1 mut

0.18 (0.035–0.87)

0.03**

FLT3-ITD

1.26 (0.1–14.96)

0.85**

DAC versus DA

0.21 (0.056–0.8)

0.023**

Molecular higher risk: NPM1−/FLT3-ITD− and FLT3-ITD+ (n = 37)

CR rate after 1st induction

OR (95% CI)

 

Age (continuous)

0.99 (0.92–1.05)

0.75*

CEBPA double mut

1.022 (0.31–3.35)

0.97*

NPM1 mut

3.7 (0.3–46)

0.28*

DAC versus DA

2.12 (0.41–11.06)

0.34*

4-year OS

HR (95% CI)

 

Age (continuous)

1.04 (0.98–1.1)

0.15*

CEBPA double mut

1.8 (0.2–15.3)

0.59*

NPM1 mut

0.79 (0.22–2.87)

0.72*

DAC versus DA

0.4 (0.14–1.15)

0.09*

4-year OS censored at allograft

HR (95% CI)

 

Age (continuous)

1.06 (0.98–1.15)

0.12**

CEBPA double mut

1.39 (0.16–12.03)

0.76**

NPM1 mut

0.18 (0.016–2.07)

0.17**

DAC versus DA

0.15 (0.03–0.77)

0,02**

  1. CI, confidence interval; CR, complete remission; HR, hazard ratio; OR, odds ratio; OS, overall survival; # computed by Chi square or Fisher exact test; ## computed by log rank test, * computed by logistic regression analysis, ** computed by Cox regression analysis.
Back to article page